TY - JOUR A1 - Tony, Hans-Peter A1 - Burmester, Gerd A1 - Schulze-Koops, Hendrik A1 - Grunke, Mathias A1 - Henes, Joerg A1 - Kötter, Ina A1 - Haas, Judith A1 - Unger, Leonore A1 - Lovric, Svjetlana A1 - Haubitz, Marion A1 - Fischer-Betz, Rebecca A1 - Chehab, Gamal A1 - Rubbert-Roth, Andrea A1 - Specker, Christof A1 - Weinerth, Jutta A1 - Holle, Julia A1 - Müller-Ladner, Ulf A1 - König, Ramona A1 - Fiehn, Christoph A1 - Burgwinkel, Philip A1 - Budde, Klemens A1 - Sörensen, Helmut A1 - Meurer, Michael A1 - Aringer, Martin A1 - Kieseier, Bernd A1 - Erfurt-Berge, Cornelia A1 - Sticherling, Michael A1 - Veelken, Roland A1 - Ziemann, Ulf A1 - Strutz, Frank A1 - von Wussow, Praxis A1 - Meier, Florian MP A1 - Hunzelmann, Nico A1 - Schmidt, Enno A1 - Bergner, Raoul A1 - Schwarting, Andreas A1 - Eming, Rüdiger A1 - Schwarz-Eywill, Michael A1 - Wassenberg, Siegfried A1 - Fleck, Martin A1 - Metzler, Claudia A1 - Zettl, Uwe A1 - Westphal, Jens A1 - Heitmann, Stefan A1 - Herzog, Anna L. A1 - Wiendl, Heinz A1 - Jakob, Waltraud A1 - Schmidt, Elvira A1 - Freivogel, Klaus A1 - Dörner, Thomas A1 - Hertl, Michael A1 - Stadler, Rudolf T1 - Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID) JF - Arthritis Research & Therapy N2 - Introduction: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin’s lymphoma in a real-life clinical setting. Methods: Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators. Results: A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician’s visual analogue scale; mean improvement from baseline of 12.1 mm) KW - GRAID Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-142856 VL - 13 IS - R75 ER - TY - JOUR A1 - Wendler, Jörg A1 - Burmester, Gerd R. A1 - Sörensen, Helmut A1 - Krause, Andreas A1 - Richter, Constanze A1 - Tony, Hans-Peter A1 - Rubbert-Roth, Andrea A1 - Bartz-Bazzanella, Peter A1 - Wassenberg, Siegfried A1 - Haug-Rost, Iris A1 - Dörner, Thomas T1 - Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients JF - Arthritis Research & Therapy N2 - INTRODUCTION: The aim of this study was to evaluate the safety and efficacy of rituximab (RTX) in a large cohort of patients with rheumatoid arthritis in routine care, and to monitor changes in daily practice since the introduction of RTX therapy. METHODS: This was a multicentre, prospective, non-interventional study conducted under routine practice conditions in Germany. Efficacy was evaluated using Disease Activity Score in 28 joints (DAS28) and Health Assessment Questionnaire-Disability Index (HAQ-DI). Safety was assessed by recording adverse drug reactions (ADRs). Physician and patient global efficacy and tolerability assessments were also evaluated. RESULTS: Overall, 2,484 patients (76.7% female, mean age 56.4 years, mean disease duration 11.7 years) received RTX treatment (22.7% monotherapy). The total observation period was approximately six-years (median follow-up 14.7 months). RTX treatment led to improvements in DAS28 and HAQ-DI that were sustained over multiple courses. DAS28 improvements positively correlated with higher rheumatoid factor levels up to 50 IU/ml. Response and tolerability were rated good/very good by the majority of physicians and patients. Mean treatment intervals were 10.5 and 6.8 months for the first and last 400 enrolled patients, respectively. Infections were the most frequently reported ADRs (9.1%; 11.39/100 patient-years); approximately 1% of patients per course discontinued therapy due to ADRs. CONCLUSIONS: Prolonged RTX treatment in routine care is associated with good efficacy and tolerability, as measured by conventional parameters and by physicians' and patients' global assessments. Rheumatoid factor status served as a distinct and quantitative biomarker of RTX responsiveness. With growing experience, physicians repeated treatments earlier in patients with less severe disease activity. KW - Rituximab Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-121184 VL - 16 IS - 2 ER - TY - THES A1 - Roth, Andrea T1 - Optimierung des Immunoblot-Nachweises von Autoantikörpern bei Blasen bildenden Autoimmundermatosen T1 - Optimisation of immunoblotting analysis for detection of autoantibodies in autoimmune bullous skin diseases N2 - Die bullösen Autoimmundermatosen sind organspezifische Autoimmunkrankheiten, die durch das Auftreten einer Autoimmunantwort gegen Strukturproteine der Haut gekennzeichnet sind. Diese Proteine sind wichtig für den Zell-Zell-Kontakt der Keratinozyten bzw. für die Adhäsion der Epidermis auf der Dermis. Die blasenbildenden Autoimmunkrankheiten werden nach den betroffenen Zielstrukturen eingeteilt. Man unterscheidet vier Hauptgruppen: die Pemphigus- und Phemphigoid-Erkrankungen, die Epidermolysis bullosa acquisita und die Dermatitis herpetiformis Duhring. Entscheidend für die Diagnosestellung von bullösen Autoimmundermatosen sind Klinik, Histologie sowie direkte und indirekte Immunfluoreszenzuntersuchung. Zur exakten Einordnung der verschiedenen bullösen Dermatosen ist die Charakterisierung der Autoantikörper durch immunserologische Tests notwendig. In der vorliegenden Arbeit beschäftigten wir uns mit der Optimierung des Immunoblotnachweises. Wir untersuchten die Seren von 120 Patienten mit bullösen Autoimmundermatosen mit Extrakten kultivierter Keratinozyten. 63 von 78 Patienten mit bullösem Pemphigoid erkannten entweder BP180 oder BP230. 16 von 18 Patienten mit Pemphigoid gestationis reagierten ebenfalls mit BP180 seltener auch mit BP230. Fünf von 6 Patienten mit Pemphigus vulgaris erkannten Desmoglein 3, einer davon zusätzlich Desmoglein 1. Zwei von 2 Patienten mit Pemphigus foliaceus reagierten mit Desmoglein 1. Fünf von 5 Patienten mit paraneoplastischem Pemphigus zeigten eine Reaktivität mit Envo-, Peri- oder Desmoplakin. Drei von 11 Patienten mit Schleimhautpemphigoid reagierten mit Laminin 5, ein Patient mit BP180. Autoantikörper gegen Kollagen Typ VII und Beta4-Integrin konnten mit Extrakten kultivierter Keratinozyten nicht nachgewiesen werden. Deshalb versuchten wir in weiteren Experimenten, den Nachweis dieser beiden Antigene zu optimieren. Zwei von 2 Patienten mit Epidermolysis bullosa acquisita erkannten Kollagen Typ VII in dermalen Extrakten und konzentriertem Überstand von kultivierten Keratinozyten. Autoantikörper gegen Beta4-Integrin konnten mit extrazellulärer Matrix von kultivierten Keratinozyten in 3 von 12 Seren von Patienten mit Schleimhautpemphigoid nachgewiesen werden. Da der Nachweis von Laminin 5 mit Extrakten kultivierter Keratinozyten nicht zufriedenstellend war, wurde auch dieser Immunoblotnachweis weiter optimiert. Wir konnten zeigen, dass die extrazelluläre Matrix kultivierter Keratinozyten ein besser geeignetes Substrat zum Nachweis von Antikörper gegen Laminin 5 ist, vor allem zum Nachweis der IgG-Subklassen. Die Ergebnisse dieser Arbeit zeigen insgesamt, dass das Extrakt kultivierter Keratinozyten den größten Teil der verschiedenen Antigene der bullösen Autoimmundermatosen enthält und somit ein effizientes Substrat für den Immunoblotnachweis darstellt. Der Nachweis von Autoantikörper gegen Laminin 5 ist zwar ebenfalls mit diesem Extrakt möglich, sensitiver ist jedoch der Nachweis unter Verwendung extrazellulärer Matrix. Mit extrazellulärer Matrix gelingt auch der Nachweis von Autoantikörpern gegen Beta4-Integrin. Weiterhin konnten wir zeigen, dass der konzentrierte Überstand von kultivierten Keratinozyten zum Nachweis von Autoantikörpern gegen Kollagen Typ VII eine gute Alternative zum dermalen Extrakt darstellt. N2 - Autoimmune bullous skin diseases are organ specific autoimmune disorders characterized by autoantibodies against various structural proteins of the skin. These proteins are responsible for cell-to-cell or cell-to-matrix adhesion. Binding of autoantibodies to these proteins results in intra-epidermal or subepidermal blisters. The autoimmune bullous skin diseases are divided into 4 main groups according to the target autoantigen: pemphigus diseases, pemphigoid diseases, epidermolysis bullosa acquisita and dermatitis herpetiformis Duhring. Decisive for the diagnosis of autoimmune bullous skin diseases are clinic, histology, direct and indirect immunofluorescence. For the exact differential diagnosis of the various autoimmune bullous skin diseases immunoserological analysis are necessary. In this study we tried to optimise the immunoblotting analysis. 120 sera from patients with autoimmune bullous skin diseases, including pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, bullous pemphigoid, pemphigoid gestationis and mucous membrane pemphigoid, were immunoblotted on the keratinocyte extract. Among the 120 sera, 95 showed detectable levels of immunoreactivity to their respective antigens. 63 of 78 sera from patients with bullous pemphigoid detected bands corresponding to BP180 and BP230. 16 of 18 sera from patients with pemphigoid gestationis reacted as well with BP180, rarely with BP230. Five of 6 sera from patient with pemphigus vulgaris recognized Desmoglein 3, one additionally Desmoglein 1. Both patients with pemphigus foliaceus reacted with Desmoglein 1. All sera from patients with paraneoplastic pemphigus detected bands corresponding to Envo-, Peri-, or Desmoplakin. Three of 11 sera from patients with mucous membrane pemphigoid reacted with laminin 5, one with BP180. Autoantibodies to type 7 collagen and beta4-integrin were not detected by immunoblotting with keratinocyte extract. Therefore, we tried to optimise the detection of autoantibodies to type 7 collagen and beta4-integrin. Both sera from patients with epidermolysis bullosa acquisita recognized type 7 collagen in dermal extract and in medium of cultured keratinocytes. In 3 of 12 patients with mucous membrane pemphigoid we were able to detect autoantibodies to beta4-integrin extracted from the extracellular matrix of human keratinocytes. In a next set of experiments, we optimised the detection of autoantibodies against laminin 5. We could show that extracellular matrix of human keratinocytes was the most sensitive substrate for the detection of autoantibodies to laminin 5. This study shows that most of the target antigens in autoimmune bullous skin diseases could be detected with immunblotting analysis using keratinocyte extract. While the detection of autoantibodies to laminin 5 with keratinocyte extract is possible, the extracellular matrix of human keratinocytes represents a more sensitive substrate. Autoantibodies to beta4-integrin can also be detected with extracellular matrix of human keratinocytes. Furthermore we can show that medium of cultured keratinozytes represents a good alternative substrate to dermal extract in the detection of autoantibodies to type 7 collagen. KW - Bullöse Autoimmundermatosen KW - Immunoblot KW - Nachweis von Autoantikörpern KW - autoimmune bullous skin diseases KW - immunoblotting analysis KW - detection of autoantibodies Y1 - 2007 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-23831 ER - TY - THES A1 - Roth, Andrea T1 - Troja in Nürnberg: Ordnungsvorstellungen des Stadtbürgers Hans Sachs in seinen Meisterliedern zum trojanischen Sagenkreis T1 - Troy in Nuremberg: concepts of order in the master songs of the citizen Hans Sachs about the cycle of the Trojan sagas N2 - Gegenstand der Dissertation sind die 26 Meisterlieder des Hans Sachs, die Episoden aus dem Trojanischen Krieg und von den Irrfahrten des Odysseus aufgreifen. Troja galt in Mittelalter und Früher Neuzeit als Prototyp des städtischen Gemeinwesens, so dass sich an seinem Fall - im doppelten Wortsinne - exemplarisch untersuchen ließ, was den Zusammenhalt des städtischen Lebens sicherte bzw. gefährdete. Der Sagenkreis um Troja bot sich für den Handwerker und Poeten Hans Sachs folglich in besonderer Weise dafür an, um Ordnungsvorstellungen für das städtische Gemeinwesen Nürnbergs abzuleiten. Die Arbeit geht von einer doppelten Fragestellung aus: Zum einen wird die Verarbeitung der literarischen Vorlage in den Meisterliedern untersucht, zum anderen wird danach gefragt, wie Hans Sachs mit seinen Liedern am zeitgenössischen Normenhorizont partizipiert und diesen seinerseits mitgestaltet. Dieser doppelte Ansatz wird bereits durch die äußere Form der Lieder nahegelegt, die sich in der Regel in narratio und moralisatio aufteilen. Die Untersuchung erfolgt in detaillierten Einzelanalysen, in denen die Lieder auch gerade auf mögliche interne Widersprüche hin befragt werden. Textgrundlage der Untersuchungen ist ein bereinigter Abdruck der Lieder nach der jeweils ältesten Handschrift; in den meisten Fällen handelt es sich jeweils um die Erstedition des Lieds. N2 - Subject of the dissertation are the 26 master songs of Hans Sachs picking up episodes from the Trojan War and the wanderings of Odysseus. Troy was considered in the Middle Ages and early modern period to be a prototype of the urban community, so that in its case - in the double sense of the word - could be studied exemplarily, which ensured or undermined the cohesion of urban life. The cycle of sagas around Troy therefore offered itself to the craftsman and poet Hans Sachs in a special way to deduce concepts of order for the urban community of Nuremberg. The work is based on a double question: On the one hand, the processing of the literary prototype in the master songs is analysed, on the other hand, it is asked how Hans Sachs participates with his songs in the contemporary context of norms and, for his part, helps shape that context. This double approach is immediately suggested by the composition of the songs, which are usually divided into narratio and moralisatio. The study is performed in detailed individual analyses interviewing the songs also for possible internal contradictions. Textual basis of the studies is an adjusted copy of the songs following the oldest manuscript; in most cases it is the first edition of the song. KW - Sachs, Hans KW - Meistersang KW - Trojanischer Sagenkreis KW - Nürnberg KW - Ordnungsvorstellungen KW - Frühe Neuzeit KW - Normenhorizont Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-160193 ER -